Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Population screening for smoldering multiple myeloma reveals high prevalence

Smoldering multiple myeloma is an asymptomatic precursor condition to multiple myeloma, a cancer in the bone marrow. We conducted a population-based screening study — in which 51% of the population over 40 years of age in Iceland participated — and found that the prevalence of smoldering multiple myeloma was 0.5% in the study population.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The prevalence of SMM.


  1. Cowan, A. J. et al. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 4, 1221–1227 (2018). A paper that describes the global burden of multiple myeloma.

  2. Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, 538–548 (2014). A paper that outlines the diagnostic criteria for multiple myeloma and its precursors.

    Article  Google Scholar 

  3. Rajkumar, S. V. et al. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 12, 129 (2022). A review article that presents arguments in support of the treatment of SMM.

  4. Vaxman, I. & Gertz, M. A. How I approach smoldering multiple myeloma. Blood 140, 828–838 (2022). A review article that presents arguments against the treatment of SMM.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rögnvaldsson, S. et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 11, 94 (2021). An article that describes the design of the iStopMM study in detail.

  6. Landgren, O. & Weiss, B. M. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 10, 1691–1697 (2009). An article that outlines the patterns of MGUS in various ethnic and racial groups.

    Article  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Thorsteinsdóttir, S. et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat. Med. (2023).

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Population screening for smoldering multiple myeloma reveals high prevalence. Nat Med 29, 313–314 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing